2 weeks Ago By Defense World Staff
Equities research analysts at StockNews.com started coverage on shares of Bio-Path ( NASDAQ:BPTH – Get Free Report ) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.
Separately, Roth Mkm reiterated a “buy” rating and set a $20.00 price objective on shares of Bio-Path in a research note on Monday, July 8th. View Our Latest Report on BPTH Bio-Path Price Performance Bio-Path ( NASDAQ:BPTH – Get Free Report ) last released its quarterly earnings data on Thursday, August 15th.
The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.54) by $0.
38. During the same quarter in the previous year, the company earned ($10.60) EPS.
As a group, equities analysts anticipate that Bio-Path will post -6.2 EPS for the current fiscal year. Institutional Investors Weigh In On Bio-Path A hedge fund recently bought a new stake in Bio-Path stock.
Armistice Capital LLC bought a new position in Bio-Path Holdings, Inc. ( NASDAQ:BPTH – Free Report ) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000.
Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors own 5.
74% of the company’s stock. About Bio-Path ( Get Free Report ) Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Further Reading Five stocks we like better than Bio-Path What is the S&P/TSX Index? CarMax’s Impressive Rally: What Investors Should Watch Next Short Selling: How to Short a Stock MarketBeat Week in Review – 9/23 – 9/27 Differences Between Momentum Investing and Long Term Investing Wake Up to This Biotech Stock That Still Has Big Potential Upside Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter ..
